[{"id":"12474215-8ccb-4758-b817-b0ea028361d5","acronym":"x-МАР","url":"https://clinicaltrials.gov/study/NCT06949982","created_at":"2025-07-19T13:21:59.299Z","updated_at":"2025-07-19T13:21:59.299Z","phase":"Phase 2","brief_title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","source_id_and_acronym":"NCT06949982 - x-МАР","lead_sponsor":"Sergey Orlov, MD","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • methotrexate • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/17/2025","start_date":" 03/17/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-05-04"},{"id":"38d96c78-7695-48ef-a4bd-d1c77b87723e","acronym":"NCI-2018-01050","url":"https://clinicaltrials.gov/study/NCT03774472","created_at":"2021-01-18T18:40:19.361Z","updated_at":"2025-02-25T14:15:17.560Z","phase":"Phase 1/2","brief_title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03774472 - NCI-2018-01050","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/20/2018","start_date":" 08/20/2018","primary_txt":" Primary completion: 04/17/2024","primary_completion_date":" 04/17/2024","study_txt":" Completion: 04/17/2024","study_completion_date":" 04/17/2024","last_update_posted":"2025-02-17"},{"id":"c3d710ea-bac1-4eba-81d4-5938ee1c0734","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464759","created_at":"2021-01-18T21:27:38.671Z","updated_at":"2025-02-25T14:29:25.619Z","phase":"Phase 1/2","brief_title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","source_id_and_acronym":"NCT04464759","lead_sponsor":"Ravi Amaravadi, MD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 10/21/2020","start_date":" 10/21/2020","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-11-21"},{"id":"8ab2b8cb-11b1-4979-b5ca-712d9486d2c4","acronym":"the HOPE trial","url":"https://clinicaltrials.gov/study/NCT04132505","created_at":"2021-01-18T20:11:03.473Z","updated_at":"2024-07-02T16:35:04.080Z","phase":"Phase 1","brief_title":"Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04132505 - the HOPE trial","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-13"},{"id":"bb2676c0-4169-4f0b-8560-87eaebe4bee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408298","created_at":"2024-05-10T20:31:50.268Z","updated_at":"2024-07-02T16:35:04.490Z","phase":"Phase 1","brief_title":"HCQ in Resectable Localized Prostate Cancer","source_id_and_acronym":"NCT06408298","lead_sponsor":"Lionel.D.Lewis, MD","biomarkers":" BNIP3","pipe":"","alterations":" ","tags":["BNIP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-10"},{"id":"d6e061d2-6993-4bd4-93d8-5c34c0e3a761","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630989","created_at":"2022-11-30T18:57:54.867Z","updated_at":"2024-07-02T16:35:10.038Z","phase":"","brief_title":"A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy","source_id_and_acronym":"NCT05630989","lead_sponsor":"Mandana Kamgar, MD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12R • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12R • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-04-11"},{"id":"0ff46655-3196-4e55-a296-9ffdaa5cc8b1","acronym":"UTAH","url":"https://clinicaltrials.gov/study/NCT04145297","created_at":"2021-01-18T20:14:00.569Z","updated_at":"2024-07-02T16:35:13.869Z","phase":"Phase 1","brief_title":"Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas","source_id_and_acronym":"NCT04145297 - UTAH","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • HRAS • RAS","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 08/18/2022","study_completion_date":" 08/18/2022","last_update_posted":"2024-03-20"},{"id":"b8db270b-31ec-42b3-ae0d-efec0f07af53","acronym":"CLEVER","url":"https://clinicaltrials.gov/study/NCT03032406","created_at":"2021-01-18T14:55:32.607Z","updated_at":"2024-07-02T16:35:15.139Z","phase":"Phase 2","brief_title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","source_id_and_acronym":"NCT03032406 - CLEVER","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER • ALK • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-03-12"},{"id":"cf76791c-2f93-4a6e-9b8d-c4c4d6a087eb","acronym":"ABBY","url":"https://clinicaltrials.gov/study/NCT04523857","created_at":"2021-12-15T16:53:42.420Z","updated_at":"2024-07-02T16:35:15.127Z","phase":"Phase 2","brief_title":"ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","source_id_and_acronym":"NCT04523857 - ABBY","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER • ALK • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-12"},{"id":"ff209a8c-ec56-43b7-adc3-aef052c2db46","acronym":"PALAVY","url":"https://clinicaltrials.gov/study/NCT04841148","created_at":"2021-04-12T15:52:32.903Z","updated_at":"2024-07-02T16:35:15.284Z","phase":"Phase 2","brief_title":"Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer","source_id_and_acronym":"NCT04841148 - PALAVY","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Bavencio (avelumab) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-03-12"},{"id":"b7222b36-4294-4a60-9a60-79c17a69cc40","acronym":"MEKiAUTO","url":"https://clinicaltrials.gov/study/NCT04214418","created_at":"2021-01-18T20:31:18.521Z","updated_at":"2024-07-02T16:35:17.433Z","phase":"Phase 1/2","brief_title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","source_id_and_acronym":"NCT04214418 - MEKiAUTO","lead_sponsor":"Columbia University","biomarkers":" KRAS • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion","tags":["KRAS • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 02/12/2020","start_date":" 02/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-28"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"5e59385c-b0a6-4594-9da3-ea1896923dc1","acronym":"NТО-RAS","url":"https://clinicaltrials.gov/study/NCT06229340","created_at":"2024-01-29T17:21:16.419Z","updated_at":"2024-07-02T16:35:21.987Z","phase":"Phase 2","brief_title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","source_id_and_acronym":"NCT06229340 - NТО-RAS","lead_sponsor":"N.N. Petrov National Medical Research Center of Oncology","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • hydroxychloroquine • leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-01-29"},{"id":"01748141-8c11-4ec6-b115-e25190e90e45","acronym":"","url":"https://clinicaltrials.gov/study/NCT02316340","created_at":"2021-01-18T10:58:33.824Z","updated_at":"2024-07-02T16:35:24.469Z","phase":"Phase 2","brief_title":"Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer","source_id_and_acronym":"NCT02316340","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Zolinza (vorinostat) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 03/07/2018","primary_completion_date":" 03/07/2018","study_txt":" Completion: 04/16/2018","study_completion_date":" 04/16/2018","last_update_posted":"2024-01-05"},{"id":"576ff15e-7a07-4123-9e2a-6f4a1fed07d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00813423","created_at":"2021-01-18T03:05:24.899Z","updated_at":"2024-07-02T16:35:41.219Z","phase":"Phase 1","brief_title":"Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy","source_id_and_acronym":"NCT00813423","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD31 • ENG • PECAM1 • BECN1","pipe":"","alterations":" ","tags":["CD31 • ENG • PECAM1 • BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2010","start_date":" 02/19/2010","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-02"},{"id":"fe45ab61-61ea-4d16-b7bb-2d511d2834aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04735068","created_at":"2021-02-02T15:52:25.047Z","updated_at":"2024-07-02T16:35:44.366Z","phase":"Phase 2","brief_title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04735068","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 04/09/2021","start_date":" 04/09/2021","primary_txt":" Primary completion: 08/21/2022","primary_completion_date":" 08/21/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-06-29"},{"id":"8790b5b4-a08c-451b-a3e9-b8bd7f87117b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04527549","created_at":"2021-01-18T21:40:53.974Z","updated_at":"2024-07-02T16:35:45.270Z","phase":"Phase 2","brief_title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","source_id_and_acronym":"NCT04527549","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-22"},{"id":"7f51bdeb-9ca6-4832-abd2-10427a80963f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01023737","created_at":"2021-01-18T04:00:54.593Z","updated_at":"2025-02-25T16:00:13.975Z","phase":"Phase 1","brief_title":"Hydroxychloroquine + Vorinostat in Advanced Solid Tumors","source_id_and_acronym":"NCT01023737","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 12/05/2017","primary_completion_date":" 12/05/2017","study_txt":" Completion: 01/08/2023","study_completion_date":" 01/08/2023","last_update_posted":"2023-02-13"},{"id":"07e1b900-2904-4919-86cd-4a1ec387e1a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04316169","created_at":"2021-01-18T20:55:10.035Z","updated_at":"2024-07-02T16:35:58.604Z","phase":"Phase 1","brief_title":"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer","source_id_and_acronym":"NCT04316169","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • CDK4","pipe":"","alterations":" ","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • hydroxychloroquine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2022-12-23"},{"id":"a9582e3e-99d1-4d84-a6a1-43c23c55626e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05647330","created_at":"2022-12-12T15:00:26.571Z","updated_at":"2024-07-02T16:35:59.264Z","phase":"Phase 2","brief_title":"Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05647330","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation • EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • hydroxychloroquine • chloroquine phosphate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-12-12"},{"id":"aae7c06f-06d4-4061-9a3e-f99e14e9f333","acronym":"","url":"https://clinicaltrials.gov/study/NCT00962845","created_at":"2021-05-06T10:52:31.702Z","updated_at":"2024-07-02T16:36:04.386Z","phase":"Phase 1","brief_title":"Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT00962845","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BECN1","pipe":"","alterations":" ","tags":["BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 05/30/2013","primary_completion_date":" 05/30/2013","study_txt":" Completion: 05/30/2013","study_completion_date":" 05/30/2013","last_update_posted":"2022-09-07"},{"id":"b051e5c2-c3f3-4658-b8ef-4b4e0a0283e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00726596","created_at":"2021-05-06T10:52:28.670Z","updated_at":"2024-07-02T16:36:08.643Z","phase":"Phase 2","brief_title":"Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer","source_id_and_acronym":"NCT00726596","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BECN1","pipe":"","alterations":" ","tags":["BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2022-06-16"},{"id":"589fc224-1f44-451f-847a-4d0ffa6361d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257424","created_at":"2021-01-18T10:36:10.936Z","updated_at":"2024-07-02T16:36:18.245Z","phase":"Phase 1/2","brief_title":"Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma","source_id_and_acronym":"NCT02257424","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600R • BRAF V600D • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2022-01-20"},{"id":"903268c5-41f0-41c5-a216-9dc491a7c313","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977470","created_at":"2021-01-18T03:48:48.527Z","updated_at":"2024-07-02T16:36:43.258Z","phase":"Phase 2","brief_title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","source_id_and_acronym":"NCT00977470","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • hydroxychloroquine"],"overall_status":"Unknown status","enrollment":" Enrollment 76","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-07-14"}]